PDCD1 and central nervous system cancer: Reardon et al. also reported that PD-L1 antibody (339.6A2) had a long-term survival effect (25%, n = 8) in mice/GL261 glioma model, although slightly less potent compared to that of PD-1 antibody (Reardon et al., 2016).